11/30/2005

Large pharmaceutical companies, followed closely by smaller competitors, are racing to get onto the market drugs that raise high-density lipoprotein cholesterol levels. Pfizer is betting the $800 million it invested in developing torcetrapib will lead to $1 billion in sales during its first year on the market, but Merck, Roche Holding, Novartis and Kos Pharmaceuticals are close behind.

Full Story:
Forbes

Related Summaries